

Original Article



Risk of Bias in Iranian Randomized Trials Included in Cochrane Reviews

Ali Kabir, MD, PhD^{1,2}; Ahmad Sofi-Mahmudi, DDS²; Arman Karimi Behnagh, MD¹; Vahid Eidkhani, MD¹; Hamid Reza Baradaran, MD, PhD^{3,2}; Payam Kabiri, MD^{4,2}; AliAkbar Haghdoost, MD, PhD^{5,2}; Bita Mesgarpour, PharmD, MPH, PhD^{2*}

¹Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran

²Cochrane Iran Associate Centre, National Institute for Medical Research Development (NIMAD), Tehran, Iran

³Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran

⁴Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

⁵Social Determinants of Health Research Centre, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran

Abstract

Background: Among interventional studies, randomized controlled trials (RCTs) provide the highest level of evidence. However, RCTs can be susceptible to the risk of bias (RoB). Systematic reviews can be performed to appraise RoB in the included articles using evaluative tools. This study aimed to describe the main characteristics and focus on the RoB of RCTs conducted in Iran and included in Cochrane Reviews (CRs).

Methods: We searched "Iran" by selecting the "Search All Text" and "Review" fields in the *Cochrane Database of Systematic Reviews* within Ovid. CRs that included the RCTs conducted in Iran were retrieved. A trial was selected only if it was included in CRs, described as a controlled clinical trial, involved human subjects and CR authors assessed its RoB. The trials were characterized by investigating the relevant articles and the table "Characteristics of included studies" in each CR. The RoB was investigated by collecting the review authors' judgments based on RoB assessment tables in the CRs.

Results: Out of 1166 Iranian RCTs included by 571 CRs, low RoB was found in 44.9% for random sequence generation, 20.8% for allocation concealment, 32.3% for blinding of participants/personnel, 36.5% for blinding of outcome assessors, 56.3% for incomplete outcome data, 41.3% for selective outcome reporting and 53.8% for other sources of bias.

Conclusion: The RoB in Iranian RCTs was found to be mostly high or unclear. While this is similar to the global situation, it is recommended that the methodological quality of conducting and reporting RCTs be addressed in Iran.

Keywords: Cochrane, Evidence-based medicine, Iran, Randomized controlled trial, Systematic review

Cite this article as: Kabir A, Sofi-Mahmudi A, Karimi Behnagh A, Eidkhani V, Baradaran HR, Kabiri P, et al. Risk of bias in Iranian randomized trials included in Cochrane reviews. Arch Iran Med. 2022;25(6):375-382. doi: 10.34172/aim.2022.61

Received: January 30, 2021, Accepted: September 15, 2021, ePublished: June 1, 2022

Introduction

Bias or systematic error can lead to over-reporting or under-reporting the treatment effects. Although randomized controlled trials (RCTs) are considered the gold standard for designing clinical research, their design, conduct, analysis and reporting are frequently at risk of flaws.¹ Moreover, results of systematic reviews, especially those focusing on interventional studies and including RCTs, mainly depend on the quality of RCTs.² Including low-quality RCTs in a systematic review can result in unreliable estimates of the effects.³ In the past decades, efforts made to improve the quality of RCTs include developing the Consolidated Standards of Reporting Trials (CONSORT).⁴ Failing to observe these standards by journals or incomplete adherence to the guidelines after their adoption, providing inadequate training for researchers and poor practices and processes of research governance in place can influence the quality of conducting and reporting in trials.⁵⁻⁸

The quality of RCTs has been frequently investigated in terms of the journal,^{9,10} the subject,^{11,12} the publication

year¹³ and rarely by the country.^{14,15} These studies have assessed the quality of reporting in trials mainly using the CONSORT statement and therefore relied on the reports' information.

Cochrane reviews (CRs) are considered the gold standard for systematic reviews owing to their implementation of the most stringent standards for quality assessment in terms of conducting and reporting.¹⁶ CRs are published in the CDSR as the most distinguished journal and database of systematic reviews and meta-analyses in healthcare. As part of the Cochrane Library, the CDSR includes all CRs and protocols prepared by authors who register titles with a CR group.¹⁷ Each CR group supports CR authors in methodological and editorial issues by focusing on a specific topic. The original Cochrane risk of bias (RoB) tool recommended for the included RCTs in 2008 was updated in 2011 and revised in 2019.^{2,18}

The number of RCTs registered in the Iranian Registry of Clinical Trials (IRCT), established as a WHO primary registry at the end of 2008,¹⁹ substantially rose to more than 25 400 in July 2020. The quality of reporting in

*Corresponding Author: Bita Mesgarpour, PharmD, MPH, PhD; Address: 21, West Fatemi St., National Institute for Medical Research Development (NIMAD), Tehran, Iran. Email: mesgarpour@research.ac.ir

Iranian RCTs has been investigated previously^{14,20-23} and it is shown that the quality of RCTs conducted in Iran might be suboptimal.

To the best of the authors' knowledge, this quality has not been evaluated yet in terms of RoB. This evaluation can also help rank countries in terms of the quality of their RCTs. This study was conducted to provide an overview of the characteristics and RoB in the RCTs conducted in Iran and included in CRs and to identify the areas requiring improvements the most.

Materials and Methods

We searched "Iran" by selecting the "Search All Text" and "Review" fields in the CDSR within Ovid on September 30, 2019. CRs were screened to identify those that included Iranian RCTs. The main characteristics extracted of the eligible CRs included DOI, publication year, CR Group, numbers of the included trials and Iranian trials and the total population of the included trials. A trial was selected only if it was included in CRs, described as a controlled clinical trial, conducted in Iran, involved human subjects and CR authors assessed its RoB.

Four independent authors, namely AK, AKB, VE and AS, extracted each trial's characteristics by investigating the table "Characteristics of included studies" in each CR and the relevant published article in case the provided data were insufficient. The collected data associated with the features of the trials included the first author's name, the article's title, language and publication year, the name of the journal, the type and beginning and end dates, city and province of the intervention, the number of centers involved, the sample size, the allocation type and RoB assessment results. RCTs, quasi-experimental studies, crossover RCTs, cluster RCTs, non-randomized and others were considered RCT assignments. The allocation type was classified as treatment, supportive care, prevention, diagnostic, and patient education following reviewing 10% of each CR group's records. Treatment was defined as any pharmaceutical intervention, and supportive care was considered any other healthcare interventions from psychologists, rehabilitation, physiotherapy, occupational therapy, dietetics, complementary therapies as well as pain specialists and social workers.²⁴

CRs appraise RoB in the included RCTs using a specific domain-based evaluative tool. RoB was judged in each criterion as 'Low risk', 'High risk', or 'Unclear risk' when there was lack of information or uncertainty over the potential for bias. To describe RoB assessments, the review authors' judgments were extracted for each criterion as an RoB assessment table in the CRs. The standard format of Cochrane RoB assessment comprises random sequence generation, allocation concealment, blinding of participants and personnel (performance bias), blinding of outcome assessors (detection bias), incomplete outcome data (attrition bias), selective outcome reporting and other sources of bias. An aggregate assessment was performed for the blinding reported in other formats such

as subjective and objective outcomes or assessor, analyst, participants and/or caregivers. The blinding category was considered low ROB if all subcategories of blinding items were reported as low ROB and it was considered as high ROB if one or more subcategories blinding items were reported as high ROB. Otherwise, the blinding bias was reported as unclear. The diverse types of bias in each CR reported as funding bias, intention-to-treat bias, sample-size bias, for-profit bias and power calculation bias were aggregated as other sources of bias where appropriate. The RoB trend in Iranian RCTs was examined to explore the role of time in improving methodology and reporting. The present study did not assess the overall RoB, given that this tool does not recommend evaluating this risk.

Statistical Analysis

The extracted data were analyzed in R version 3.6.0 (2019-04-26) (R Foundation for Statistical Computing, Vienna, Austria; <http://www.R-project.org>). The RCTs were characterized using frequency and relative frequency.

Results

The RoB had been assessed for 1166 out of 1894 Iranian RCTs included in 571 retrieved CRs. The RCTs in the retrieved CRs were excluded mainly due to being an ongoing type of trial (20.6%) or their assessment being pending (20.6%) (Figure 1).

A total of 7.3% (2.7% of the population) of 15 894 RCTs recruiting an entire population of 5 461 452 and included in the CRs were conducted in Iran and their RoB had been assessed. Five CRs with an unknown population were, however, excluded from the analysis. Fifty CR groups produced 63.7% of the CRs from 1970 to 2018 after 2013 (Figure 2). The majority of Iranian RCTs addressed pregnancy and childbirth (n=250, 21.4%), gynecology and fertility (n=158, 13.5%) and skin and oral health (n=70, 6.0%). A CR entitled "Interventions for old world cutaneous leishmaniasis" by members of the Cochrane Skin Group in Madrid published in 2017 included the highest number of Iranian RCTs, i.e. 27 out of a total of 49.²⁵ No Iranian RCTs were reviewed by Cochrane HIV/AIDS, Lung Cancer, Methodology, STI and Urology groups. Two Iranian RCTs were included in two CRs and the RoB assessment performed in one of them was inconsistent.

The majority (81.0%) of the study Iranian RCTs were performed between 2003 and 2016 in 60 cities. Figure 3 shows the heterogeneous distribution of the location of the centers where the RCTs were performed, with the highest number performed in provinces of Tehran (n=348, 29.8%), Isfahan (n=148, 12.7%) and Fars (n=97, 8.3%). However, reporting was insufficient for the year of conducting the study in 465 studies, the month of beginning of the trial in 283 further studies, the name of the city in 107 studies and the number or name of the centers involved in the trial in 202 studies.

These studies were published as an article (n=1149),




Figure 1. Flow Diagram of Search for Iranian RCTs in Cochrane Reviews.




Figure 2- Distribution of conducting sites of Iranian RCTs. Plot created using R package version 3.6.0 (2019-04-26) (R Foundation for Statistical Computing, Vienna, Austria; <http://www.R-project.org>).

abstract in conference proceedings ($n = 10$), IRCT registry ($n = 6$) and a PhD dissertation. The articles were published in 521 peer-reviewed journals, mostly in English (90.1%) and in domestic journals (33.6%). *Journal of Research in Medical Sciences*, Isfahan University of Medical Sciences ($n = 29$), the *International Journal of Gynecology & Obstetrics* ($n = 29$) and the *Iranian Red Crescent Medical Journal* ($n = 28$) published the highest number of these articles.

The assignments included an RCT type in 1040 cases (89.2%), a quasi-experimental type in 26 (2.2%) and unclear in one study. Crossover: 21, other: 14, cluster: 7. The treatment (47.3%) and supportive care (24.2%) constituted the most common allocation types.

The majority of the RCTs' (83.6%) sample sizes were 30-200 with a median of 80, over 1000 in four of the studies and at most 50 in 25.5%. The Cochrane Airways group reviewed an RCT with a sample size of 12514 as the




Figure 3. Distribution of Iranian RCTs in the Cochrane reviews based on Cochrane Review Groups. BC, Breast Cancer; CaC, Consumers and Communication; CC, Childhood Cancer; DCI, Dementia and Cognitive Improvement; HM, Haematological Malignancies; HT, Hypertension; MSK, musculoskeletal; NM, Neuromuscular; SCZ, Schizophrenia; Vsc, Vascular.

maximum and the Public Health group reviewed an RCT with a sample size of 9 as the minimum. The full text of two of the articles was also inaccessible. Table 1 presents the sample size frequency.

From a methodological perspective, at least one arm was used as the control group in 1077 (92.4%) studies, including 299 (25.6%) that provided this group with a placebo. Moreover, 414 (35.5%) studies were double-blinded, 28 (2.4%) triple-blinded and 266 (22.8%) used no blinding methods in their design.

Not all the domains of the RoB tool were assessed in all the CRs; for instance, Cochrane reviewers had assessed random sequence generation in 1134 out of the 1166 RCTs and allocation concealment in 1122. Performance and attrition biases respectively received the highest frequency of high RoB (22.9%) and low RoB (56.3%). The RoB of at least one domain was judged as unclear in 931 (79.8%) out of the 1166 included RCTs. Figure 4 shows the RoB assessed in the individual domains of the RoB tool for the included RCTs. According to Figure 5, random sequence generation and incomplete outcome data continuously improved in terms of increasing low RoB during 2002–2017 (The analysis for all domains has been provided in Supplementary file 1).

Discussion

This study sought to investigate the quality of Iranian RCTs included in CRs based on Cochrane reviewers’ evaluations. To the best of the authors’ knowledge, this study pioneered RCTs’ quality evaluation at a national scale using the Cochrane RoB tool. The quality of Iranian RCTs was found to be low in terms of the majority of RoB domains with a high or unclear RoB, which were mostly associated with the study design and included random sequence generation, allocation concealment and

Table 1. Frequency of Sample Size Groups in Iranian RCTs

Sample Size Group	No. (%)	Cumulative
9–20	34 (2.9)	34 (2.9)
21–40	160 (13.7)	194 (16.6)
41–60	232 (19.9)	426 (36.5)
61–80	176 (15.1)	602 (51.6)
81–100	169 (14.5)	771 (66.1)
101–150	188 (16.1)	959 (82.2)
151–200	87 (7.4)	1046 (89.6)
201–300	59 (5.1)	1105 (94.7)
301–400	29 (2.5)	1134 (97.2)
401–500	9 (0.9)	1149 (98.1)
501–1000	18 (1.5)	1161 (99.6)
1001–12514	5 (0.4)	1166 (100)

blinding.

A few studies mainly assessed RCTs of special subjects or fields using the CONSORT checklist and yielded consistent findings, suggesting the poor methodological quality and reporting of the Iranian RCTs.^{21,26–29}

The present study found the RoB of 44.9% of the Iranian RCTs to be low and 6.0% to be high in terms of random sequence generation. In contrast, the remaining RCTs’ status was impossible to be evaluated in terms of randomization given the inadequate data. Similarly, randomization was invalidated in 35.5%–98.7% of Iranian RCTs owing to their failure to report their randomization method, as was the case for the RCTs conducted in other countries^{26,30,31}; for instance, low RoB was reported in terms of randomization for 44% and 62% of RCTs performed in Saudi Arabia¹⁵ and Sub-Saharan Africa region,³² respectively. There are some studies that assessed a large number of RCTs in all subjects and countries. For




Figure 4. Overall Risk of Bias Assessment of Iranian RCTs Included and Evaluated in Cochrane Reviews.




Figure 5. Trend of Low RoB for Four Domains of Cochrane Tool in the Iranian RCTs during 2002–2017.

example, low RoB was also reported for below 50% of 1286 RCTs included in CRs.³³ Another study with 176,620 RCTs showed that 36.4% and 50.9% of RCTs still suffer from high RoB in random sequence generation and allocation concealment, respectively.³⁴ Given that this problem is not specific to Iran, it is recommended that efforts be made at a global scale to enhance the quality of RCTs in this domain.

Blinding was assessed as two subdomains, i.e., blinding of participants and personnel (performance bias) and blinding of outcome assessors and analysts (detection bias). In terms of performance bias, only 32.3% (n=262) of the included studies were assessed as low-risk, while 299 studies used placebos as the method of blinding their participants and personnel. This difference between

the number of low-risk studies and that of studies using placebos shows Iranian researchers' failure to comprehend the mechanism of implementing placebos to hide interventions from the participants or indicates their inability to adequately explain the mechanism in a way that Cochrane reviewers are persuaded with the explanation. One-third of the studies were also evaluated as low-risk in terms of detection bias, which can be explained by Iranians' unwillingness to participate in completely-blinded trials and failure to report the study details, which made it difficult for the reviewers to assess bias. Research generally suggests inadequately-performed blinding in the RCTs conducted in Iran and other countries.^{15,33,35}

Low RoB was assigned to attrition bias in 56.3% of cases, suggesting a small number of patients failing to follow

up in the Iranian RCTs. In line with studies assessing Iranian RCTs in this domain, the present study found that Iranian researchers are relatively successful in providing data on the patients withdrawing from the study. Studies conducted in countries other than Iran have also reported the RoB of many RCTs as low in this domain.^{15,33} Low RoB was assigned to selective outcome reporting in 436 (41.3%) RCTs and unclear RoB to 453 (42.9%). This high frequency of unclear RoB can be explained by the failure of the majority of Iranian authors to register their studies in databases such as the IRCT, which resulted in failing to publish the study protocol before the final results were published. The reviewers had therefore, difficulty evaluating this domain based on the outcomes reported in the article. Given the generally difficult assessment of selective outcome reporting and other bias domains,³⁶ these results should be cautiously interpreted.

Unclear RoB is a result of poor reporting. Although poor reporting does not necessarily mean flawed methodology, it hinders adequate assessment of the reliability of the methods and trustworthiness of the results.³⁷ A study conducted in 2017 assessed 20920 RCTs included in CRs in terms of poor reporting and inadequate methods.³⁸ When comparing the results of that study with ours, Iranian RCTs had moderately higher unclear RoB in allocation concealment (71.7% vs 57.5%). Besides, unclear RoB was also higher in random sequence generation and incomplete outcome data domains. This reflects the need to train Iranian researchers regarding research methodology and reporting. Furthermore, including a research methodologist should be considered by Iranian research teams.

In our study, the Iranian RCTs included a small sample, which was below 60 in their majority. The distribution of the sites of conducting the RCTs was also heterogeneous, and many of the studies were unicenter and conducted in Tehran, the capital of Iran, which can be explained by the significantly higher number of universities and top medical universities located in Tehran compared to other cities and provinces. It is recommended that more collaborative, multi-center and high-quality studies be conducted by making appropriate research policies.

Evaluation of the quality of RCTs in the different field of medical sciences showed the same pattern; for example, only 11.1% of dentistry and oral health RCTs were deemed to be of low overall RoB³⁹ or while the quantity of trials in hand surgery has increased over time, the methodological quality has remained low.⁴⁰ Still, with the urgent need for the best available evidence through RCTs during the COVID-19 pandemic, we see the disparity between desired standards and what is done in the real world when conducting and reporting RCTs.⁴¹

According to Chalmers and Glasziou, an estimated significant portion (85%) of medical research is wasted in many dimensions and phases, namely relevance of the research question to the patients and physicians, appropriateness of the study design, accessibility of full

text and unbiased and usable reporting.⁴² The present findings suggest that the limitations of Iranian RCTs include all these four dimensions. Some of these issues, e.g., low-quality reporting, could be simply avoided. The introduction of the CONSORT statement in 1996⁴ has increased the percentage of studies with low RoB in randomization, blinding of outcome assessors, incomplete data reporting and other sources of bias. However, the high frequency of unclear RoB in all the domains can be an alarming sign of low-quality reporting in Iranian RCTs.

The strengths of the present study include evaluation of the RCTs by third-party reviewers with no prejudices or bias. This also could be a limitation of this study, as we considered that assessments are correct. RoB was, however, differently reported in different CRs for the same RCT. This discrepancy was also raised in previous assessments of RoB based on the Cochrane tool.⁴³

In conclusions, the present study showed that conducting and reporting of the Iranian RCTs could be improved in several domains. Despite the major improvements observed between the initial and the most recent RCTs, special attention should be paid to methodological training in certain domains such as allocation concealment and blinding. However, this shortcoming has been addressed globally and can be overcome by training and development of interventional policies.

Acknowledgements

The authors would like to acknowledge and thank Maryam Hosseinzadeh for her help on retrieving included studies.

Authors' Contribution

AK, HRB, PK, AH and BM conceived the study and were responsible for the design and draft of the manuscript. ASM, AKB, VE and BM were responsible for data collection, analysis, interpretation and first draft of the manuscript. ASM conducted the analyses. All authors critically revised and approved the manuscript.

Availability of Data and Materials

All data and materials are available from the corresponding author upon request.

Conflict of Interest Disclosures

The authors declare that there is no conflict of interest.

Ethics Statement

Not applicable.

Funding

This work was partly supported by a research grant from National Institute for Medical Research Development in Iran (Grant Number: 962656).

Supplementary Materials

Supplementary file 1. Time trend for proportion of low, high, and unclear risk of bias in each domain.

References

- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928. doi: [10.1136/bmj.d5928](https://doi.org/10.1136/bmj.d5928).
- Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing

- risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, eds. *Cochrane Handbook for Systematic Reviews of Interventions*. John Wiley & Sons; 2019. p. 205-28. doi: [10.1002/9781119536604.ch8](https://doi.org/10.1002/9781119536604.ch8).
3. Verhagen AP, de Vet HC, de Bie RA, Boers M, van den Brandt PA. The art of quality assessment of RCTs included in systematic reviews. *J Clin Epidemiol*. 2001;54(7):651-4. doi: [10.1016/s0895-4356\(00\)00360-7](https://doi.org/10.1016/s0895-4356(00)00360-7).
 4. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *JAMA*. 1996;276(8):637-9. doi: [10.1001/jama.276.8.637](https://doi.org/10.1001/jama.276.8.637).
 5. Gohel MS, Chetter I. Are clinical trials units essential for a successful trial? *BMJ*. 2015;350:h2823. doi: [10.1136/bmj.h2823](https://doi.org/10.1136/bmj.h2823).
 6. Kane JM, Leucht S. Unanswered questions in schizophrenia clinical trials. *Schizophr Bull*. 2008;34(2):302-9. doi: [10.1093/schbul/sbm143](https://doi.org/10.1093/schbul/sbm143).
 7. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *JAMA*. 2001;285(15):1987-91. doi: [10.1001/jama.285.15.1987](https://doi.org/10.1001/jama.285.15.1987).
 8. Xu L, Li J, Zhang M, Ai C, Wang L. Chinese authors do need CONSORT: reporting quality assessment for five leading Chinese medical journals. *Contemp Clin Trials*. 2008;29(5):727-31. doi: [10.1016/j.cct.2008.05.003](https://doi.org/10.1016/j.cct.2008.05.003).
 9. Lai TY, Wong VW, Lam RF, Cheng AC, Lam DS, Leung GM. Quality of reporting of key methodological items of randomized controlled trials in clinical ophthalmic journals. *Ophthalmic Epidemiol*. 2007;14(6):390-8. doi: [10.1080/09286580701344399](https://doi.org/10.1080/09286580701344399).
 10. Rios LP, Oduyungbo A, Moitri MO, Rahman MO, Thabane L. Quality of reporting of randomized controlled trials in general endocrinology literature. *J Clin Endocrinol Metab*. 2008;93(10):3810-6. doi: [10.1210/jc.2008-0817](https://doi.org/10.1210/jc.2008-0817).
 11. Lu L, Liao M, Zeng J, He J. Quality of reporting and its correlates among randomized controlled trials on acupuncture for cancer pain: application of the CONSORT 2010 Statement and STRICTA. *Expert Rev Anticancer Ther*. 2013;13(4):489-98. doi: [10.1586/era.13.27](https://doi.org/10.1586/era.13.27).
 12. Ziogas DC, Zintzaras E. Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement. *Ann Epidemiol*. 2009;19(7):494-500. doi: [10.1016/j.annepidem.2009.03.018](https://doi.org/10.1016/j.annepidem.2009.03.018).
 13. Clark L, Schmidt U, Tharmanathan P, Adamson J, Hewitt C, Torgerson D. Poor reporting quality of key randomization and allocation concealment details is still prevalent among published RCTs in 2011: a review. *J Eval Clin Pract*. 2013;19(4):703-7. doi: [10.1111/jep.12031](https://doi.org/10.1111/jep.12031).
 14. Nojomi M, Ramezani M, Ghafari-Anvar A. Quality of reports on randomized controlled trials published in Iranian journals: application of the new version of consolidated standards of reporting trials (CONSORT). *Arch Iran Med*. 2013;16(1):20-2.
 15. Rajab AM, Hamza A, Aldairi RK, Alaloush MM, Saquib J, Saquib N. Systematic review on the quality of randomized controlled trials from Saudi Arabia. *Contemp Clin Trials Commun*. 2019;16:100441. doi: [10.1016/j.conctc.2019.100441](https://doi.org/10.1016/j.conctc.2019.100441).
 16. Sharif MO, Janjua-Sharif FN, Ali H, Ahmed F. Systematic reviews explained: AMSTAR-how to tell the good from the bad and the ugly. *Oral Health Dent Manag*. 2013;12(1):9-16.
 17. Starr M, Chalmers I, Clarke M, Oxman AD. The origins, evolution, and future of The Cochrane Database of Systematic Reviews. *Int J Technol Assess Health Care*. 2009;25 Suppl 1:182-95. doi: [10.1017/s026646230909062x](https://doi.org/10.1017/s026646230909062x).
 18. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:l4898. doi: [10.1136/bmj.l4898](https://doi.org/10.1136/bmj.l4898).
 19. Soleymani-Dodaran M, Khalili D, Hosseini H, Najafi L, Kamali K, Ranjbar P, et al. Iranian Registry of Clinical Trials two years on and the timing of registrations. *J Evid Based Med*. 2011;4(3):168-71. doi: [10.1111/j.1756-5391.2011.01146.x](https://doi.org/10.1111/j.1756-5391.2011.01146.x).
 20. Habib Agahi R, Navabi N, Shahravan A, Ghassemi A. Critical appraisal of reporting randomized clinical trials published in Iranian dental journals during 2003-2010. *J Dent (Tehran)*. 2014;11(3):310-8.
 21. Gohari F, Baradaran HR, Tabatabaee M, Anjizani S, Mohammadpour Tousekani F, Atlasi R, et al. Quality of reporting randomized controlled trials (RCTs) in diabetes in Iran; a systematic review. *J Diabetes Metab Disord*. 2015;15(1):36. doi: [10.1186/s40200-016-0258-2](https://doi.org/10.1186/s40200-016-0258-2).
 22. Habibi A, Salehi A, Molavi Vardanjani H. Quality assessment of randomized controlled trials of Iranian traditional medicine: an eight-year study. *Eur J Integr Med*. 2020;33:101040. doi: [10.1016/j.eujim.2019.101040](https://doi.org/10.1016/j.eujim.2019.101040).
 23. Ayatollahi SM, Jafari P, Ghaem H. An evaluation of the quality of published clinical trials in Iranian medical journals during 2001-2004. *J Babol Univ Med Sci*. 2005;7(4):64-70. [Persian].
 24. Ahmedzai SH, Walsh D. Palliative medicine and modern cancer care. *Semin Oncol*. 2000;27(1):1-6.
 25. Heras-Mosteiro J, Monge-Maillou B, Pinart M, Lopez Pereira P, Reveiz L, Garcia-Carrasco E, et al. Interventions for old world cutaneous leishmaniasis. *Cochrane Database Syst Rev*. 2017;12(12):CD005067. doi: [10.1002/14651858.CD005067.pub5](https://doi.org/10.1002/14651858.CD005067.pub5).
 26. Adib-Hajbaghery M, Adib M, Eshraghi Arani N. Evaluating the quality of randomized trials published in Persian nursing journals with more than 10 years of publishing using the CASP checklist. *Iran Journal of Nursing*. 2017;30(109):1-9. doi: [10.29252/ijn.30.109.1](https://doi.org/10.29252/ijn.30.109.1). [Persian].
 27. Alamri HM, Alharbi F. Quality assessment of randomized clinical trials reporting in endodontic journals: an observational study from 2012 to 2017. *J Endod*. 2018;44(8):1246-50. doi: [10.1016/j.joen.2018.05.011](https://doi.org/10.1016/j.joen.2018.05.011).
 28. Faizi F, Tavallaee A, Rahimi A, Saburi A, Saghafia M. Quality assessment of randomized control trials applied psychotherapy for chronic pains in Iran: a systematic review of domestic trials. *Iran Red Crescent Med J*. 2014;16(9):e15312. doi: [10.5812/ircmj.15312](https://doi.org/10.5812/ircmj.15312).
 29. Mehrazmay A, Karambakhsh A, Salesi M. Reporting quality assessment of randomized controlled trials published in nephrology urology monthly journal. *Nephrourol Mon*. 2015;7(4):e28752. doi: [10.5812/numonthly.28752](https://doi.org/10.5812/numonthly.28752).
 30. Hosseini SM, Ahmadiania H, Rezaeian M. Evaluation of the quality of writing of the title and abstract of randomized controlled clinical trial papers published in the journals of the Iran's Universities of Medical Sciences in 2016, based on the CONSORT checklist: a descriptive study. *J Rafsanjan Univ Med Sci*. 2019;18(3):267-84. [Persian].
 31. Taghipour A, Shakeri MT, Yousefi R, Barzanouni S. Assessment of randomized controlled clinical trials articles in the Journal of Dental School, Mashhad University of Medical Sciences: published 2003-2015. *J Mashhad Dent Sch*. 2017;41(1):11-20. doi: [10.22038/jmids.2017.8123](https://doi.org/10.22038/jmids.2017.8123).
 32. Ndounga Diakou LA, Ntoui F, Ravaud P, Boutron I. Avoidable waste related to inadequate methods and incomplete reporting of interventions: a systematic review of randomized trials performed in sub-Saharan Africa. *Trials*. 2017;18(1):291. doi: [10.1186/s13063-017-2034-0](https://doi.org/10.1186/s13063-017-2034-0).
 33. Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P. Avoidable waste of research related to inadequate methods in clinical trials. *BMJ*. 2015;350:h809. doi: [10.1136/bmj.h809](https://doi.org/10.1136/bmj.h809).
 34. Vinkers CH, Lamberink HJ, Tijdkink JK, Heus P, Bouter L,

- Glasziou P, et al. The methodological quality of 176,620 randomized controlled trials published between 1966 and 2018 reveals a positive trend but also an urgent need for improvement. *PLoS Biol.* 2021;19(4):e3001162. doi: [10.1371/journal.pbio.3001162](https://doi.org/10.1371/journal.pbio.3001162).
35. Nagai K, Saito AM, Saito TI, Kaneko N. Reporting quality of randomized controlled trials in patients with HIV on antiretroviral therapy: a systematic review. *Trials.* 2017;18(1):625. doi: [10.1186/s13063-017-2360-2](https://doi.org/10.1186/s13063-017-2360-2).
 36. Hartling L, Bond K, Vandermeer B, Seida J, Dryden DM, Rowe BH. Applying the risk of bias tool in a systematic review of combination long-acting beta-agonists and inhaled corticosteroids for persistent asthma. *PLoS One.* 2011;6(2):e17242. doi: [10.1371/journal.pone.0017242](https://doi.org/10.1371/journal.pone.0017242).
 37. Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A. Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. *J Clin Epidemiol.* 2012;65(6):602-9. doi: [10.1016/j.jclinepi.2011.10.016](https://doi.org/10.1016/j.jclinepi.2011.10.016).
 38. Dechartres A, Trinquart L, Atal I, Moher D, Dickersin K, Boutron I, et al. Evolution of poor reporting and inadequate methods over time in 20920 randomised controlled trials included in Cochrane reviews: research on research study. *BMJ.* 2017;357:j2490. doi: [10.1136/bmj.j2490](https://doi.org/10.1136/bmj.j2490).
 39. Sofi-Mahmudi A, Iranparvar P, Shakiba M, Shamsoddin E, Mohammad-Rahimi H, Naseri S, et al. Quality assessment of studies included in Cochrane oral health systematic reviews: a meta-research. *Int J Environ Res Public Health.* 2021;18(14):7284. doi: [10.3390/ijerph18147284](https://doi.org/10.3390/ijerph18147284).
 40. Long C, desJardins-Park HE, Popat R, Fox PM. Quality of surgical randomized controlled trials in hand surgery: a systematic review. *J Hand Surg Eur Vol.* 2018;43(8):801-7. doi: [10.1177/1753193418780184](https://doi.org/10.1177/1753193418780184).
 41. Bonini S, Maltese G. COVID-19 clinical trials: quality matters more than quantity. *Allergy.* 2020;75(10):2542-7. doi: [10.1111/all.14409](https://doi.org/10.1111/all.14409).
 42. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *Lancet.* 2009;374(9683):86-9. doi: [10.1016/s0140-6736\(09\)60329-9](https://doi.org/10.1016/s0140-6736(09)60329-9).
 43. Jordan VM, Lensen SF, Farquhar CM. There were large discrepancies in risk of bias tool judgments when a randomized controlled trial appeared in more than one systematic review. *J Clin Epidemiol.* 2017;81:72-6. doi: [10.1016/j.jclinepi.2016.08.012](https://doi.org/10.1016/j.jclinepi.2016.08.012).